Regulatory2026-07-28
RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3)
Replimune Group Inc.REPL
- Indication
- Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)
- Stage
- phase5
- Event
- Regulatory Decision
- Source
- View catalyst source ↗